Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;15(2):2287073.
doi: 10.1080/19490976.2023.2287073. Epub 2023 Dec 3.

Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review

Susanna Meade  1   2 , Jeremy Liu Chen Kiow  1   2 , Cristian Massaro  3   4 , Gurpreet Kaur  2   3 , Elizabeth Squirell  1   2 , Brian Bressler  1   2 , Genelle Lunken  2   3   4
Affiliations

Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review

Susanna Meade et al. Gut Microbes. 2023 Dec.

Abstract

Loss of response to therapy in inflammatory bowel disease (IBD) has led to a surge in research focusing on precision medicine. Three systematic reviews have been published investigating the associations between gut microbiota and disease activity or IBD therapy. We performed a systematic review to investigate the microbiome predictors of response to advanced therapy in IBD. Unlike previous studies, our review focused on predictors of response to therapy; so the included studies assessed microbiome predictors before the proposed time of response or remission. We also provide an update of the available data on mycobiomes and viromes. We highlight key themes in the literature that may serve as future biomarkers of treatment response: the abundance of fecal SCFA-producing bacteria and opportunistic bacteria, metabolic pathways related to butyrate synthesis, and non-butyrate metabolomic predictors, including bile acids (BAs), amino acids, and lipids, as well as mycobiome predictors of response.

Keywords: Crohn’s disease; Inflammatory bowel disease; immunosuppressive therapy; metabolome; microbiome; treatment response; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

BB: Advisor/speaker: Ferring, Janssen, Abbvie, Takeda, Pfizer, Novartis, BMS, Merck, Sandoz, Organon, and Lifelabs. Advisor: Alimentiv, Gilead, Iterative Scopes, AMT, Celgene, Merck, Amgen, Pendopharm, Genentech, BMS, Allergan, Protagonist, Fresenius Kabi, Mylan, Viatris, Bausch Health, Celltrion Healthcare, BioJamp Pharma, and Eupraxia. Research support: Janssen, Abbvie, GSK, BMS, Amgen, Genentech, and Merck. Stock Options: Qu Biological. SM: received speaker fees from Falk Pharma. JLCK, CM, GK, GL nil to declare.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram.
Figure 2.
Figure 2.
Microbial diversity.
Figure 3.
Figure 3.
Related microbial predictors of response of therapy.
See this image and copyright information in PMC

References

    1. Zhang YZ, Li YY.. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91–29. doi: 10.3748/wjg.v20.i1.91. - DOI - PMC - PubMed
    1. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655–662. doi: 10.1038/s41586-019-1237-9. - DOI - PMC - PubMed
    1. Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter CJ, et al. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol. 2018;9(1):e132. doi: 10.1038/ctg.2017.58. - DOI - PMC - PubMed
    1. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011;60:631. doi: 10.1136/gut.2010.223263. - DOI - PubMed
    1. Zhou Y, Xu ZZ, He Y, Yang Y, Liu L, Lin Q, Nie Y, Li M, Zhi F, Liu S, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018;3:3. doi: 10.1128/mSystems.00188-17. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources